ARCHIVES

FDA News: FDA Approved A Supplemental New Drug Application For Nexavar Tablets (Sorafenib) For The Treatment Of Patients With Locally Recurrent Or Metastatic, Progressive, Differentiated Thyroid Carcinoma Refractory To Radioactive Iodine Treatment.

This article is from The Cancer Letter archive.

Vol. 39 No. 45 | December 17, 2013

Download PDF Visit The Full Archive

Related Articles

Letters To The Editor From I-ELCAP’s Claudia Henschke and Steve Walker From Abigail Alliance.

July 8, 2011

GAO Calls For Stronger FDA Enforcement Of Accelerated Approval Followup Studies

October 30, 2009

NCI Program Review: Report calls For Two Types Of Centers: Comprehensive And All Others

October 18, 1996

In Brief: Accidents Claim Wisconsin’s William Caldwell, John Wear; Murchison, Nance To Head Nalsi

June 15, 1979

Seattle Cancer Care Alliance Marks its 10th Anniversary—January 2011

June 28, 2021

Breast Cancer Action Claims “Victory On Avastin.”

December 14, 2007